IN THE NEWS

« Previous Release | Next Release »

BOTHELL, Wash., -- Cardiac Science Corporation, a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, has joined with Gust Bardy, MD to create an innovation center focused on the development and commercialization of simple, cost-effective medical products and services that positively impact public health.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

"Dr. Bardy shares our vision for the future of medicine and the growing importance of primary, remote, and self-directed care," said Dave Marver, Cardiac Science president and chief executive officer. "He is a proven thought-leader, researcher, clinician, and entrepreneur. We are pleased to forge this long-term relationship with Dr. Bardy to drive innovation and create value."

Under the agreement, Dr. Bardy will lead the Innovation Center within Cardiac Science to develop and commercialize advancements in medical technology and services. The Innovation Center will join Cardiac Science resources with Dr. Bardy's network of physician and research colleagues to focus on novel developments that simplify patient care with improved outcomes.

Dr. Bardy currently leads the Seattle Institute for Cardiovascular Research, where he served as Director and Primary Investigator for several significant trials in cardiology, including the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) and the Home AED Trial (HAT). He is also founder and board member of Cameron Health, Inc. and is clinical professor of medicine in cardiology and cardiac electrophysiology at University of Washington. Dr. Bardy has obtained more than 350 patents worldwide.

"With their broad reach into primary care and general cardiology offices, Cardiac Science is an ideal partner. I am passionate about making it easier for patients to access medical care and effectively navigate the healthcare system," said Gust Bardy, MD. "Dave and the team at Cardiac Science embrace change. I'm excited to be working with them and look forward to bringing many new ideas to physicians and their patients."

About Cardiac Science

Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT

For more information, contact (media) info@cardiacscience.com | (investors) ir@optoindia.com | +91.80.2852.8088